APTEVO THERAPEUTICS INC (APVO) Stock Price, Quote, News and Overview
NASDAQ:APVO - Nasdaq - US03835L3069 - Common Stock - Currency: USD
APVO Quote, Performance and Key Statistics
3.47
+0.06 (+1.76%)
The current stock price of APVO is 3.47 USD. In the past month the price decreased by -24.73%. In the past year, price decreased by -98.42%.
APVO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About APVO
Company Profile
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. The company is headquartered in Seattle, Washington and currently employs 40 full-time employees. The company went IPO on 2016-07-20. The company is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. The company has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and APVO711, are developed using its ADAPTIR modular protein technology platform. Its preclinical candidate APVO442 is developed using its ADAPTIR-FLEX modular protein technology platform. APVO436 is a bispecific ADAPTIR that is designed to engage CD3 and CD123 to redirect T-cells to destroy leukemia cells expressing the target CD123 molecule on their surface. ALG.APV-527 is a novel investigational bispecific ADAPTIR candidate. APVO603 is a preclinical dual agonist bispecific ADAPTIR candidate designed to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family.
Company Info
APTEVO THERAPEUTICS INC
2401 4th Ave Ste 1050
Seattle WASHINGTON 98121 US
CEO: Marvin L. White
Employees: 40
Company Website: http://aptevotherapeutics.com/
Phone: 12068380500
APTEVO THERAPEUTICS INC / APVO FAQ
What is the stock price of APTEVO THERAPEUTICS INC today?
The current stock price of APVO is 3.47 USD. The price increased by 1.76% in the last trading session.
What is the ticker symbol for APTEVO THERAPEUTICS INC stock?
The exchange symbol of APTEVO THERAPEUTICS INC is APVO and it is listed on the Nasdaq exchange.
On which exchange is APVO stock listed?
APVO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for APTEVO THERAPEUTICS INC stock?
7 analysts have analysed APVO and the average price target is 208.85 USD. This implies a price increase of 5918.59% is expected in the next year compared to the current price of 3.47. Check the APTEVO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is APTEVO THERAPEUTICS INC worth?
APTEVO THERAPEUTICS INC (APVO) has a market capitalization of 1.74M USD. This makes APVO a Nano Cap stock.
How many employees does APTEVO THERAPEUTICS INC have?
APTEVO THERAPEUTICS INC (APVO) currently has 40 employees.
What are the support and resistance levels for APTEVO THERAPEUTICS INC (APVO) stock?
APTEVO THERAPEUTICS INC (APVO) has a resistance level at 3.94. Check the full technical report for a detailed analysis of APVO support and resistance levels.
Should I buy APTEVO THERAPEUTICS INC (APVO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of APVO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of APVO, evaluating the profitability, health, valuation and growth aspects
- APTEVO THERAPEUTICS INC (APVO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- APTEVO THERAPEUTICS INC (APVO) Sales and EPS estimates to see what analysts future expectations are.
- APTEVO THERAPEUTICS INC (APVO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- APTEVO THERAPEUTICS INC (APVO) Insider and Institutional Ownership to learn about the owners and their transactions.
- APTEVO THERAPEUTICS INC (APVO) Stock Chart to make your own analysis
- APTEVO THERAPEUTICS INC (APVO) Latest news and press-releases to stay up to date.
Does APTEVO THERAPEUTICS INC (APVO) stock pay dividends?
APVO does not pay a dividend.
When does APTEVO THERAPEUTICS INC (APVO) report earnings?
APTEVO THERAPEUTICS INC (APVO) will report earnings on 2025-03-03, after the market close.
What is the Price/Earnings (PE) ratio of APTEVO THERAPEUTICS INC (APVO)?
APTEVO THERAPEUTICS INC (APVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-453.86).
What is the Short Interest ratio of APTEVO THERAPEUTICS INC (APVO) stock?
The outstanding short interest for APTEVO THERAPEUTICS INC (APVO) is 8.73% of its float. Check the ownership tab for more information on the APVO short interest.
APVO Technical Analysis
APVO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to APVO. The financial health of APVO is average, but there are quite some concerns on its profitability.
APVO Financial Highlights
Over the last trailing twelve months APVO reported a non-GAAP Earnings per Share(EPS) of -453.86. The EPS decreased by -350.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -167.24% | ||
| ROE | -559.13% | ||
| Debt/Equity | 0 |
APVO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to APVO. The Buy consensus is the average rating of analysts ratings from 7 analysts.